Organon & Co. (OGN) — 分析摘要
Organon & Co.(OGN)的市值为3.56十亿美元,最近一年的营收同比增长了-2.9%。净利润率为3.0%。当前市盈率为17.0倍。
核心要点
- 营收同比变化-2.9%
- 净利润率3.0%
- 市盈率17.0倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比,OGN的营收增长为-2.9%,市盈率为17.0倍。
Organon & Co. (OGN)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗,在依赖任何估值输出前应先重点核查这些风险。
Debt/EBITDA 为 7.7x — 高杠杆,存在再融资风险
利息保障倍数为 0.0x — 盈利不足以覆盖利息支出
D/E 为 8.5x — 杠杆极高
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
10,000
总部
JERSEY CITY, NJ
Exchange
XNYS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
年度每股股息
$0.08
股息收益率
0.59%
股息历史
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。